Search the Newsreel

ResMed Inc (ASX:RMD) climbs as RBA eases pressure

ResMed Inc (ASX:RMD) saw a significant increase in its share price, climbing 3.77% to $30.04 on July 29, 2026, outperforming the S&P/ASX 200 Health Care Index. This rise occurred amidst broad positive sentiment in the healthcare sector, with inflation cooling, suggesting a potential for …

RMD|Resmed Inc|Price:195.270|Chg%:+3.440

Resmed Inc. (RMD) is a holding company specializing in medical devices and cloud-based software for respiratory disorders such as sleep-disordered breathing and chronic obstructive pulmonary disease. The company's segments include Sleep and Breathing Health and Residential Care Software. Key financial data from Q1 2026 …

Resmed Inc (RMD) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Resmed Inc (RMD), listing its major shareholders and their respective proportions. It also provides a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activity with changes in holdings for key institutions. Additionally, it …

ResMed (ASX:RMD) Dividend Outlook: What Income Investors Are Watching?

Resmed Inc (RMD) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides a historical overview of dividend payouts and stock splits for Resmed Inc (RMD). It lists various cash dividends, including their gross amounts, record dates, payment dates, and ex-dividend dates, spanning from 2023 to projected dates in 2026. The company has distributed …

Resmed Inc (RMD) Earnings Date & Reports & Earnings News

ResMed Inc. Revenue Breakdown – NYSE:RMD

Resmed Inc (0KW4) Q1 2024 Earnings Report - Results, Call & Slides

Resmed Inc. (0KW4) reported its Q1 2024 earnings, beating the consensus EPS estimate by $0.02 with an actual EPS of $1.64. The company's revenue, however, slightly missed expectations at $1.10 billion, but still represented a 16.00% year-over-year growth. The report includes details on the …

ResMed Stock Is Down 30% From Its Peak While Free Cash Flow Just Hit a Record $1.7 Billion

ResMed (NYSE: RMD) stock has fallen 30% from its peak due to fears that GLP-1 weight loss drugs will reduce the addressable market for sleep apnea treatment, despite the company's strong business results. The company, a leader in sleep apnea devices, reported significant revenue …

ResMed Target Price Cut 10% to A$40.00/Share by Canaccord Genuity>RMD.AU

Canaccord Genuity has adjusted its target price for ResMed (RMD.AU), cutting it by 10% to A$40.00 per share. This rating change reflects a revised outlook on the company's valuation.

ResMed Earnings Growth Seen Strong as Ventilator Issue Clouds FY27, UBS Says

UBS projects strong earnings growth for ResMed, driven by a robust CPAP cycle and its digital health platform. However, concerns about the expiration of a ventilator contract in FY27 could impact future earnings, creating investor uncertainty. The firm has a Neutral rating on ResMed …

UBS lowers ResMed stock price target to $300 on valuation By Investing.com

UBS has lowered its price target for ResMed Inc. (NYSE:RMD) to $300 from $312, while maintaining a Buy rating, citing valuation concerns. Despite the target reduction, the firm believes ResMed, currently trading at $197.83, is undervalued and anticipates strong earnings growth driven by increased …

Is ResMed Stock a Buy After the Noctrix Acquisition?

RBC Downgrades ResMed to Sector Perform From Outperform, Cuts Price Target to $234 From $276

RBC has downgraded ResMed (RMD) from "Outperform" to "Sector Perform" and reduced its price target from $276 to $234. This report published on July 17, 2026, reflects a more cautious outlook on the medical equipment company. The downgrade comes amid a series of recent …

How Investors Are Reacting To ResMed (RMD) Downgrade Amid FY27 Cost and Supply Pressures

RBC Capital recently downgraded ResMed (RMD) to Sector Perform due to anticipated FY27 pressures, including Astral ventilator replacements, higher input costs, and supply constraints. This downgrade highlights how operational challenges in a single product line can significantly impact sales, cost structure, and future business …

Resmed to sell MatrixCare business to PE firm Frazier Healthcare Partners

Resmed has agreed to sell its MatrixCare business, which includes related software brands like Healthcare First and Citus, to private equity firm Frazier Healthcare Partners. This divestiture allows Resmed to focus on its core sleep health, respiratory care, and connected home-based healthcare segments. Frazier …

Precision Trading with Resmed Inc. (RMD) Risk Zones

This article provides a detailed analysis of Resmed Inc. (RMD) with a focus on risk zones and trading strategies based on AI models. It highlights near-term weak sentiment, mid-term strength, and a broader long-term weak bias, alongside specific entry and target points for various …

ResMed Inc. stock rises Thursday, outperforms market

ResMed Inc. (RMD) stock rose 2.11% on Thursday, closing at $202.76, despite a broader market decline where the S&P 500 Index and Dow Jones Industrial Average both fell. This marks the second consecutive day of gains for ResMed.

ResMed Inc. stock rises Wednesday, outperforms market

ResMed Inc. (RMD) stock increased by 2.88% to $198.57 on Wednesday, outperforming the broader market. This rise ended a three-day losing streak for the company's stock. The S&P 500 Index and the Dow Jones Industrial Average also saw gains on the same day.

Mizuho Adjusts Price Target on ResMed to $220 From $235, Maintains Outperform Rating

Mizuho has adjusted its price target for ResMed (RMD) to $220 from the previous $235, while maintaining an Outperform rating on the stock. The article also briefly mentions Unity Software's Q4 financial results, reporting revenue of $609 million which beat estimates, and a quarterly …

ResMed Price Target Cut 1.8% to A$40.97/Share by Morgans

Morgans has reduced its price target for ResMed (RMD) by 1.8% to A$40.97 per share. This adjustment comes despite the company's previous financial filings and ongoing market performance. Investors may want to monitor RMD's stock movement closely following this revised outlook from Morgans.

Resmed sets Aug. 6 webcast for fiscal Q4 results

ResMed Shares Downgraded: Trimmed Price Target Offers Some Comfort To Bulls

ResMed (ASX:RMD) Q3 Results 2026: Is the ASX Healthcare Stock Back on Track?

ResMed Stock Fell 8% This Week. Here’s What a Strong Earnings Beat Means for the Recovery Case

ResMed Shares Hit New Low Following Earnings: The Latest Look

Resmed reports double-digit revenue and profit increases in Q3 FY26

ResMed (ASX:RMD) Stock Analysis: Share Performance, Earnings Growth, and Digital Health Expansion

Resmed posts Q2 FY26 earnings growth, lifts dividend